AstraZeneca and Daiichi Sankyo Report Encouraging Results From Enhertu Trial

By PacConAdmin | February 24, 2022

AstraZeneca and Daiichi Sankyo have released promising results from a phase 3 study of Enhertu (trastuzumab deruxtecan), saying the drug significantly improved both progression-free and overall survival in patients with HER2-low metastatic breast cancer.
Source: Drug Industry Daily

Posted in Drug Industry Daily